Company Evogene Ltd.

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:13 2024-05-16 am EDT			5-day change	1st Jan Change
249.1 ^ILa	-3.86%		-6.35%	-16.91%

Apr. 02	Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd	CI
Mar. 20	Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq	MT

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Number of employees: 142

USD in Million	2022	Weight	2023	Weight	Delta
Agriculture 67.2 %	1	52.3 %	4	67.2 %	+332.76%
Industrial Applications 19.1 %	0	4.3 %	1	19.1 %	+1,393.06%
Human Health 8.6 %	1	30.6 %	0	8.6 %	-5.07%
Unallocated 5.1 %	0	12.8 %	0	5.1 %	+34.11%

USD in Million	2022	Weight	2023	Weight	Delta
United States 65.0 %	1	51.0 %	4	65.0 %	+329.15%
Others 19.0 %	0	4.0 %	1	19.0 %	+1,499.40%
Israel 16.0 %	1	45.0 %	1	16.0 %	+19.72%

Managers	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	58	01-12-31
Yaron Eldad DFI	Director of Finance/CFO	57	22-03-31
Mark Kapel CTO	Chief Tech/Sci/R&D Officer	48	04-12-31
Eyal Ronen PRN	Corporate Officer/Principal	-	22-05-31
Sassi Masliah PRN	Corporate Officer/Principal	-	10-12-31
Liat Foigel Wejgman HRO	Human Resources Officer	-	14-12-31
Nir Arbel PRN	Corporate Officer/Principal	-	21-07-31
Yisrael Gewirtz AUD	Comptroller/Controller/Auditor	47	-

Members of the board	Title	Age	Since
Dan Falk BRD	Director/Board Member	79	21-11-16
Sarit Firon CHM	Chairman	58	16-08-10
Leon Recanati BRD	Director/Board Member	76	05-04-30
Ofer Haviv CEO	Chief Executive Officer	58	01-12-31
Oded Shoseyov BRD	Director/Board Member	67	18-10-31
Nir Nimrodi BRD	Director/Board Member	55	22-08-31
Adrian Percy BRD	Director/Board Member	59	19-02-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	50,584,888	49,746,029 ( 98.34 %)	0	98.34 %

Name	Equities	%	Valuation
SilverArc Capital Management LLC 6.100 %	3,085,503	6.100 %	2 M ILa
Leon Recanati 1.658 %	838,859	1.658 %	562 321 ILa
Morgan Stanley Capital Services LLC 0.5615 %	284,048	0.5615 %	190 409 ILa
KSM Mutual Funds Ltd. 0.5468 %	276,605	0.5468 %	185 419 ILa
Migdal Mutual Funds Ltd. 0.2878 %	145,591	0.2878 %	97 595 ILa
P&S Vermögensberatungs AG Performance & Sicherheit 0.1977 %	100,000	0.1977 %	67 034 ILa
BNP Paribas Arbitrage SA 0.1807 %	91,400	0.1807 %	61 269 ILa
Excellence Nessuah Mutual Funds Management Ltd. 0.1456 %	73,648	0.1456 %	49 369 ILa
LPL Financial LLC 0.1321 %	66,835	0.1321 %	44 802 ILa
UBS Financial Services, Inc. 0.1235 %	62,495	0.1235 %	41 893 ILa

Evogene Ltd.

13 Gad Feinstein Street Park Rehovot

7638517, Rehovot

http://www.evogene.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOGENE LTD.	-16.91%	34.13M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research